<DOC>
	<DOCNO>NCT02563561</DOCNO>
	<brief_summary>This Phase 3 , randomize , multicenter , multi-arm , placebo-controlled , double-blind study apaziquone patient ≤4 non-muscle invasive bladder tumor , ≤3.5 cm diameter , must fully resect TURBT . In addition Screening , patient undergo assessment urothelial carcinoma bladder via cystoscopy clinically apparent tumor Ta , G1-G2 . Following TURBT Day 1 , eligible patient randomize one three treatment arm 1:1:1 ratio : Arm 1 : One dose Apaziquone Arm 2 : Two Doses Apaziquone Arm 3 : Placebo Primary endpoint evaluate Time Recurrence either one instillation 4 mg apaziquone two instillation 4 mg apaziquone relative placebo instillation follow TURBT patient non-muscle invasive bladder cancer ( NMIBC ) receive transurethral resection bladder tumor ( TURBT ) .</brief_summary>
	<brief_title>A Study Intravesical Apaziquone Surgical Adjuvant Patient Undergoing TURBT</brief_title>
	<detailed_description>This Phase 3 , randomize , multicenter , multi-arm , placebo-controlled , double-blind study apaziquone patient ≤4 non-muscle invasive bladder tumor , ≤3.5 cm diameter , must fully resect TURBT . In addition Screening , patient undergo assessment urothelial carcinoma bladder via cystoscopy clinically apparent tumor Ta , G1-G2 . Following TURBT Day 1 , eligible patient randomize one three treatment arm 1:1:1 ratio : Arm 1 : One Dose Apaziquone : - Day 1 : administration 4 mg apaziquone 60±30 minute post-TURBT - Day 15 ( ±5 day ) : administration placebo Arm 2 : Two Doses Apaziquone : - Day 1 : administration 4 mg apaziquone 60±30 minute post-TURBT - Day 15 ( ±5 day ) : administration 4 mg apaziquone Arm 3 : Placebo : - Day 1 : administration placebo 60±30 minute post-TURBT - Day 15 ( ±5 day ) : administration placebo Once randomize , Day 1 study drug instillation occur 60 ±30 minute post TURBT . Patients return Day 15 ( ±5 day ) second instillation unless pathology result available show non Ta , G1-G2 histology ; absence local pathology result Day 15 visit , patient receive second instillation study drug . All histology specimen review local pathology laboratory clinical treatment decision study analysis base local pathology review . Patients whose pathology Ta , G1-G2 follow safety Day 35 ( ±5 day ) last dose study drug discontinue study . Patients pathology confirm Ta , G1-G2 disease follow accord schedule : - Cystoscopic examination urine cytology every 90 day ( ±10 day ) ( calculated date TURBT ) 24 month tumor recurrence progression . - If time 24 month follow period tumor recurrence , patient continue study follow-up cystoscopic examination urine cytology every 90 day ( ±10 day ) ( calculated date TURBT ) end 24 month . Patients recurrence permit follow-up TURBT . - If time 24 month follow period tumor recurrence and/or patient start another therapy , patient follow telephone , safety every 90 day ( ±10 day ) ( calculated date TURBT ) end 24 month . Duration Study : The duration study patient approximately 24 month include : - Screening Period : 30-days - Treatment Period : Day 1 Day 15 ( ±5 day ) - Safety Follow-up Period : 24-months</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Apaziquone</mesh_term>
	<criteria>1 . Patient must diagnosis urothelial carcinoma bladder clinically apparent tumor Ta , G1G2 . 2 . Patient ≤4 tumor , none exceed 3.5 cm diameter . 3 . Patient must willing give write informed consent must able adhere dose visit schedule , meet study requirement . 4 . Patient least 18 year age randomization . 5 . Patient must willing practice two form contraception , one must barrier method , study entry least 35 day last dose study drug . 6 . Females childbearing potential must negative pregnancy test within 30 day prior randomization . Females postmenopausal least 1 year ( define 12 month since last menses ) surgically sterilize require test . 1 . Patient active concurrent malignancy/lifethreatening disease . If history prior malignancies/lifethreatening disease , patient disease free least 5 year . Patients prior malignancy less 5 year study entry may still enrol receive treatment result complete resolution cancer currently clinical , radiologic , laboratory evidence active recurrent disease . 2 . Patient positive urine cytology malignancy Screening . 3 . Patient active uncontrolled infection , include urinary tract infection , underlie medical condition , serious illness would impair ability patient receive protocol treatment . 4 . Patient use investigational drug , biologics , device within 30 day prior study treatment plan use course study . 5 . Patient prior intravesical chemotherapy , immunotherapy , previous exposure apaziquone . 6 . Patient ever Upper tract Transitional Cell Carcinoma ( TCC ) . Urethral tumor ( prostatic urethra include ) . Any invasive bladder tumor know tumor Ta , G1G2 . Any evidence lymph node distant metastasis . Any bladder tumor histology TCC . Carcinoma situ ( CIS ) . 7 . Patient tumor bladder diverticulum . 8 . Patient receive pelvic radiotherapy ( include external beam and/or brachytherapy . ) 9 . Patient bleed disorder screen platelet count &lt; 100×109/L . 10 . Patient screen hemoglobin &lt; 10 mg/dL . 11 . Patient unstable medical condition would make unsafe undergo TURBT . 12 . Patient history interstitial cystitis . 13 . Patient history allergy red color food dye . 14 . For patient recurrent tumor , patient least 6month cystoscopicallyconfirmed tumorfree interval last tumor recurrence screen cystoscopic examination . 15 . Patient pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Bladder Cancer</keyword>
	<keyword>Non-muscle invasive bladder cancer</keyword>
	<keyword>Apaziquone</keyword>
	<keyword>TURBT</keyword>
	<keyword>Stage Ta , G1-G2</keyword>
</DOC>